These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35618200)

  • 1. Amikacin pharmacokinetics in elderly patients with severe infections.
    Medellín-Garibay SE; Romano-Aguilar M; Parada A; Suárez D; Romano-Moreno S; Barcia E; Cervero M; García B
    Eur J Pharm Sci; 2022 Aug; 175():106219. PubMed ID: 35618200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients.
    Kato H; Parker SL; Roberts JA; Hagihara M; Asai N; Yamagishi Y; Paterson DL; Mikamo H
    Antibiotics (Basel); 2021 Jan; 10(2):. PubMed ID: 33498481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.
    Medellín-Garibay SE; Ortiz-Martín B; Rueda-Naharro A; García B; Romano-Moreno S; Barcia E
    J Antimicrob Chemother; 2016 Feb; 71(2):471-9. PubMed ID: 26568565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
    Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
    Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
    Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Predictive Dosing Nomogram to Achieve PK/PD Targets of Amikacin Initial Dose in Critically Ill Patients: A Non-Parametric Approach.
    Coste A; Bellouard R; Deslandes G; Jalin L; Roger C; Ansart S; Dailly E; Bretonnière C; Grégoire M
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.
    Illamola SM; Colom H; van Hasselt JG
    Br J Clin Pharmacol; 2016 Sep; 82(3):793-805. PubMed ID: 27198625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
    Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates.
    Matcha S; Dillibatcha J; Raju AP; Chaudhari BB; Moorkoth S; Lewis LE; Mallayasamy S
    Paediatr Drugs; 2023 May; 25(3):365-375. PubMed ID: 36943583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize
    Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model.
    Thirion DJG; Pasche V; Matouk E; Marsot A
    Pediatr Pulmonol; 2020 May; 55(5):1154-1160. PubMed ID: 32119197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.
    Illamola SM; Huynh HQ; Liu X; Bhakta ZN; Sherwin CM; Liou TG; Carveth H; Young DC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
    Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR
    Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
    Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
    Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis.
    Praet A; Bourguignon L; Vetele F; Breant V; Genestet C; Dumitrescu O; Doleans-Jordheim A; Reix P; Goutelle S
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0073721. PubMed ID: 34280011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach.
    Pérez-Blanco JS; Sáez Fernández EM; Calvo MV; Lanao JM; Martín-Suárez A
    J Antimicrob Chemother; 2020 Aug; 75(8):2222-2231. PubMed ID: 32363405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.